Przejdź do zawartości
Merck

Etidronate disodium in the treatment of Paget's disease of bone.

Annals of internal medicine (1982-05-01)
S M Krane
ABSTRAKT

Control of Paget's disease of bone has been possible through treatment with agents that decrease bone resorption; calcitonins, diphosphonates, and mithramycin. The pagetic lesion is not, however, cured. Etidronate disodium is one of the diphosphonates. The clinical improvement attained with this drug has to be set against adverse effects, of which pain is probably the most bothersome in practice. Clinical remission can last as long as 2 years after treatment is stopped.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Etidronate disodium, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Etidronate disodium hydrate, ≥97% (NMR), solid